• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

索磷布韦/维帕他韦在接受阿片类药物替代疗法的慢性丙型肝炎病毒感染患者中的疗效和安全性：3期ASTRAL试验分析

Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.

作者信息

Grebely Jason, Dore Gregory J, Zeuzem Stefan, Aspinall Richard J, Fox Raymond, Han Lingling, McNally John, Osinusi Anu, Brainard Diana M, Subramanian G Mani, Natha Macky, Foster Graham R, Mangia Alessandra, Sulkowski Mark, Feld Jordan J

机构信息

The Kirby Institute, University of New South Wales Australia, Sydney.

Johann Wolfgang Goethe University Medical Center, Frankfurt am Main, Germany.

出版信息

Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23.

DOI:10.1093/cid/ciw579
PMID:27553377
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5106608/
Abstract

In this analysis of the ASTRAL trials (non-opioid substitution therapy [OST], n = 984; OST, n = 51) evaluating the once-daily, pan-genotypic regimen of sofosbuvir/velpatasvir for hepatitis C virus infection, OST did not impact completion, adherence, sustained virologic response (SVR12), or safety. SVR12 was 96% (95% confidence interval, 87%, >99%) in those receiving OST.

摘要

在这项对ASTRAL试验（非阿片类替代疗法[OST]，n = 984；阿片类替代疗法，n = 51）的分析中，评估了索磷布韦/维帕他韦每日一次的泛基因型方案用于丙型肝炎病毒感染的情况，阿片类替代疗法对完成率、依从性、持续病毒学应答（SVR12）或安全性没有影响。接受阿片类替代疗法的患者中，SVR12为96%（95%置信区间，87%，>99%）。

相似文献

1
Efficacy and Safety of Sofosbuvir/Velpatasvir in Patients With Chronic Hepatitis C Virus Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ASTRAL Trials.索磷布韦/维帕他韦在接受阿片类药物替代疗法的慢性丙型肝炎病毒感染患者中的疗效和安全性：3期ASTRAL试验分析
Clin Infect Dis. 2016 Dec 1;63(11):1479-1481. doi: 10.1093/cid/ciw579. Epub 2016 Aug 23.
2
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.索磷布韦维帕他韦片治疗失代偿期肝硬化的丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2618-28. doi: 10.1056/NEJMoa1512614. Epub 2015 Nov 16.
3
Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.索磷布韦和维帕他韦联合利巴韦林或不联合利巴韦林治疗丙型肝炎病毒基因型 3 感染合并肝硬化患者的疗效。
Gastroenterology. 2018 Oct;155(4):1120-1127.e4. doi: 10.1053/j.gastro.2018.06.042. Epub 2018 Jun 27.
4
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.索磷布韦/维帕他韦联合治疗方案治疗曾接受治疗的 1 型或 3 型丙型肝炎病毒感染患者：一项随机试验。
Ann Intern Med. 2015 Dec 1;163(11):809-17. doi: 10.7326/M15-1014. Epub 2015 Nov 10.
5
Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.德国单一中心研究索磷布韦/维帕他韦和来迪派韦/索磷布韦治疗丙型肝炎的真实世界疗效和安全性。
PLoS One. 2019 Apr 4;14(4):e0214795. doi: 10.1371/journal.pone.0214795. eCollection 2019.
6
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.索磷布韦和维帕他韦治疗 2 型和 3 型丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.
7
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.在接受阿片类药物替代治疗的慢性 HCV 基因 1 型感染患者中，使用 Ledipasvir/Sofosbuvir 联合或不联合利巴韦林的疗效和安全性：ION 三期试验分析。
Clin Infect Dis. 2016 Dec 1;63(11):1405-1411. doi: 10.1093/cid/ciw580. Epub 2016 Aug 23.
8
Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.索磷布韦和维帕他韦治疗近期有注射吸毒史的丙型肝炎病毒感染（SIMPLIFY）：一项开放标签、单臂、4 期、多中心试验。
Lancet Gastroenterol Hepatol. 2018 Mar;3(3):153-161. doi: 10.1016/S2468-1253(17)30404-1. Epub 2018 Jan 6.
9
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.索磷布韦和维帕他韦联合或不联合利巴韦林治疗丙型肝炎病毒相关失代偿性肝硬化的患者报告结局：来自随机、开放标签 ASTRAL-4 期 3 期试验的探索性分析。
Lancet Gastroenterol Hepatol. 2016 Oct;1(2):122-132. doi: 10.1016/S2468-1253(16)30009-7. Epub 2016 Aug 3.
10
Resistance analysis in patients with genotype 1-6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies.在 III 期研究中，用索非布韦/维帕他韦治疗基因型 1-6 HCV 感染患者的耐药性分析。
J Hepatol. 2018 May;68(5):895-903. doi: 10.1016/j.jhep.2017.11.032. Epub 2017 Dec 6.

引用本文的文献

1
Cost-effectiveness analysis of emergency department-based hepatitis C screening and linkage-to-care program.基于急诊科的丙型肝炎筛查和衔接治疗方案的成本效益分析。
BMC Health Serv Res. 2024 Oct 30;24(1):1308. doi: 10.1186/s12913-024-11793-4.
2
GRAND PLAN: Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of Hepatitis C Virus Infection Among People Initially Disengaged From Health Care Who Use Drugs-A Systematic Multidisciplinary Approach.宏伟计划：格卡瑞韦/哌柏西普治疗丙型肝炎病毒感染在最初脱离医疗保健的吸毒者中的安全性和有效性——一种系统的多学科方法。
Open Forum Infect Dis. 2024 Mar 5;11(3):ofad638. doi: 10.1093/ofid/ofad638. eCollection 2024 Mar.
3
Evaluation of Hepatitis C Treatment Outcomes Among Patients Enrolled in Outpatient Parenteral Antibiotic Therapy-Boston, Massachusetts, 2016-2021.2016年至2021年马萨诸塞州波士顿接受门诊胃肠外抗生素治疗的患者丙型肝炎治疗结果评估
Open Forum Infect Dis. 2023 Jul 5;10(7):ofad342. doi: 10.1093/ofid/ofad342. eCollection 2023 Jul.
4
Predictors of hepatitis C cure among people who inject drugs treated with directly observed therapy supported by peer case managers in Kenya.肯尼亚接受同伴个案管理员支持的直接观察治疗的注射吸毒者中丙型肝炎治愈的预测因素。
Int J Drug Policy. 2023 Mar;113:103959. doi: 10.1016/j.drugpo.2023.103959. Epub 2023 Feb 7.
5
Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment.从 ACTG 5360 MINMON 试验看依从性：慢性丙型肝炎治疗中采用 12 周 Sofosbuvir/Velpatasvir 最低监测方案。
Clin Infect Dis. 2023 Jun 8;76(11):1959-1968. doi: 10.1093/cid/ciad034.
6
Hepatitis C models of care: approaches to elimination.丙型肝炎护理模式：消除丙型肝炎的方法。
Can Liver J. 2020 Jun 4;3(2):165-176. doi: 10.3138/canlivj.2019-0002. eCollection 2020 Spring.
7
Hepatitis C Virus Infection in Persons Who Inject Drugs in the Middle East and North Africa: Intervention Strategies.中东和北非地区注射吸毒人群中的丙型肝炎病毒感染：干预策略。
Viruses. 2021 Jul 14;13(7):1363. doi: 10.3390/v13071363.
8
Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination.慢性病毒性肝炎综合管理的进展与挑战：消除的关键途径。
World J Gastroenterol. 2021 Jul 14;27(26):4004-4017. doi: 10.3748/wjg.v27.i26.4004.
9
Drug-Drug Interactions of Newly Approved Direct-Acting Antiviral Agents in Patients with Hepatitis C.丙型肝炎患者中新获批的直接作用抗病毒药物的药物相互作用
Int J Gen Med. 2021 Jan 28;14:289-301. doi: 10.2147/IJGM.S283910. eCollection 2021.
10
Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care.在基层医疗中推广 HCV 评估模型以促进 HCV 治疗的成本效益分析。
PLoS One. 2020 Jun 17;15(6):e0234577. doi: 10.1371/journal.pone.0234577. eCollection 2020.

本文引用的文献

1
Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.在接受阿片类药物替代治疗的慢性 HCV 基因 1 型感染患者中，使用 Ledipasvir/Sofosbuvir 联合或不联合利巴韦林的疗效和安全性：ION 三期试验分析。
Clin Infect Dis. 2016 Dec 1;63(11):1405-1411. doi: 10.1093/cid/ciw580. Epub 2016 Aug 23.
2
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.依巴司韦/格拉瑞韦治疗接受阿片类激动剂治疗的丙型肝炎病毒感染者：一项随机试验。
Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9.
3
Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.丙型肝炎病毒获得持续病毒学应答后晚期复发或再感染的风险：一项系统评价和荟萃分析。
Clin Infect Dis. 2016 Mar 15;62(6):683-694. doi: 10.1093/cid/civ948. Epub 2016 Jan 19.
4
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.索磷布韦和维帕他韦治疗 2 型和 3 型丙型肝炎病毒感染。
N Engl J Med. 2015 Dec 31;373(27):2608-17. doi: 10.1056/NEJMoa1512612. Epub 2015 Nov 17.
5
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.索磷布韦和维帕他韦治疗 1、2、4、5、6 型 HCV 感染。
N Engl J Med. 2015 Dec 31;373(27):2599-607. doi: 10.1056/NEJMoa1512610. Epub 2015 Nov 16.
6
Recommendations for the management of hepatitis C virus infection among people who inject drugs.注射吸毒者丙型肝炎病毒感染管理建议
Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17.
7
EASL Recommendations on Treatment of Hepatitis C 2015.2015年欧洲肝脏研究学会丙型肝炎治疗指南
J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21.
8
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.奥贝他韦/帕利瑞韦/达塞布韦联合利巴韦林治疗接受美沙酮或丁丙诺啡维持治疗的 HCV 基因 1 型感染患者。
J Hepatol. 2015 Aug;63(2):364-9. doi: 10.1016/j.jhep.2015.03.029. Epub 2015 Apr 1.
9
Treatment of hepatitis C virus infection among people who are actively injecting drugs: a systematic review and meta-analysis.治疗活跃性注射毒品人群中的丙型肝炎病毒感染：系统评价和荟萃分析。
Clin Infect Dis. 2013 Aug;57 Suppl 2:S80-9. doi: 10.1093/cid/cit306.
10
Epidemiology and natural history of HCV infection.丙型肝炎病毒感染的流行病学和自然史。
Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):553-62. doi: 10.1038/nrgastro.2013.107. Epub 2013 Jul 2.